MARKET

ADAG

ADAG

Adagene Inc.
NASDAQ
3.100
+0.120
+4.03%
After Hours: 3.069 -0.032 -1.02% 19:32 02/11 EST
OPEN
2.960
PREV CLOSE
2.980
HIGH
3.100
LOW
2.860
VOLUME
58.16K
TURNOVER
--
52 WEEK HIGH
3.190
52 WEEK LOW
1.300
MARKET CAP
146.11M
P/E (TTM)
-4.8159
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ADAG last week (0202-0206)?
Weekly Report · 2d ago
Adagene (ADAG): De-Risked CTLA-4 Asset, Emerging Regulatory Clarity, and Strategic Partnerships Underpin Buy Rating
TipRanks · 3d ago
Weekly Report: what happened at ADAG last week (0126-0130)?
Weekly Report · 02/02 10:15
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Adagene (ADAG) and Johnson & Johnson (JNJ)
TipRanks · 01/26 12:20
Weekly Report: what happened at ADAG last week (0119-0123)?
Weekly Report · 01/26 10:14
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/23 21:05
Adagene Outlines 2026 Clinical Milestones and Reports $74.5 Million Year-End Cash Runway
TipRanks · 01/23 13:25
Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026
Benzinga · 01/23 13:21
More
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Webull offers Adagene Inc (ADR) stock information, including NASDAQ: ADAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAG stock methods without spending real money on the virtual paper trading platform.